Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 6.65
(-8.65%)
SEK 6.65
(-8.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -194.7 Million SEK | -55.76% |
| 2022 | -125 Million SEK | 10.59% |
| 2021 | -139.81 Million SEK | 50.63% |
| 2020 | -283.18 Million SEK | -11.06% |
| 2019 | -254.98 Million SEK | -10.92% |
| 2018 | -229.87 Million SEK | 25.73% |
| 2017 | -309.53 Million SEK | 21.44% |
| 2016 | -393.99 Million SEK | -682.36% |
| 2015 | -50.36 Million SEK | 49.66% |
| 2014 | -100.04 Million SEK | -102.92% |
| 2013 | -49.3 Million SEK | 16.16% |
| 2012 | -58.8 Million SEK | 35.05% |
| 2011 | -90.54 Million SEK | -15833.93% |
| 2010 | -568.26 Thousand SEK | -49.37% |
| 2009 | -380.44 Thousand SEK | 46.96% |
| 2008 | -717.28 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -132.5 Million SEK | 31.95% |
| 2024 Q2 | -82.1 Million SEK | 38.04% |
| 2023 Q1 | -239.7 Million SEK | -91.76% |
| 2023 Q3 | -82.3 Million SEK | 53.21% |
| 2023 Q2 | -175.9 Million SEK | 26.62% |
| 2023 Q4 | -194.7 Million SEK | -136.57% |
| 2023 FY | -194.7 Million SEK | -55.76% |
| 2022 Q3 | -188.6 Million SEK | 17.93% |
| 2022 FY | -125 Million SEK | 10.59% |
| 2022 Q4 | -125 Million SEK | 33.72% |
| 2022 Q1 | -103 Million SEK | 26.33% |
| 2022 Q2 | -229.8 Million SEK | -123.11% |
| 2021 Q1 | -245.25 Million SEK | 13.39% |
| 2021 Q3 | -168.63 Million SEK | 16.74% |
| 2021 FY | -139.81 Million SEK | 50.63% |
| 2021 Q4 | -139.81 Million SEK | 17.09% |
| 2021 Q2 | -202.52 Million SEK | 17.42% |
| 2020 FY | -283.18 Million SEK | -11.06% |
| 2020 Q3 | -159.42 Million SEK | 13.58% |
| 2020 Q4 | -283.18 Million SEK | -77.63% |
| 2020 Q2 | -184.47 Million SEK | 16.57% |
| 2020 Q1 | -221.11 Million SEK | 13.28% |
| 2019 Q1 | -257.91 Million SEK | -12.2% |
| 2019 FY | -254.98 Million SEK | -10.92% |
| 2019 Q4 | -254.98 Million SEK | 11.04% |
| 2019 Q3 | -286.63 Million SEK | 10.27% |
| 2019 Q2 | -319.43 Million SEK | -23.85% |
| 2018 Q4 | -229.87 Million SEK | 8.15% |
| 2018 FY | -229.87 Million SEK | 25.73% |
| 2018 Q3 | -250.26 Million SEK | 6.29% |
| 2018 Q2 | -267.05 Million SEK | 9.27% |
| 2018 Q1 | -294.34 Million SEK | 4.91% |
| 2017 Q1 | -382.04 Million SEK | 3.03% |
| 2017 Q4 | -309.53 Million SEK | 12.65% |
| 2017 Q3 | -354.34 Million SEK | 2.59% |
| 2017 FY | -309.53 Million SEK | 21.44% |
| 2017 Q2 | -363.74 Million SEK | 4.79% |
| 2016 Q2 | -31.66 Million SEK | 27.51% |
| 2016 Q3 | -23.59 Million SEK | 25.5% |
| 2016 Q4 | -393.99 Million SEK | -1570.19% |
| 2016 FY | -393.99 Million SEK | -682.36% |
| 2016 Q1 | -43.68 Million SEK | 13.26% |
| 2015 Q1 | -86.07 Million SEK | 13.97% |
| 2015 Q4 | -50.36 Million SEK | 15.09% |
| 2015 FY | -50.36 Million SEK | 49.66% |
| 2015 Q2 | -69.58 Million SEK | 19.15% |
| 2015 Q3 | -59.31 Million SEK | 14.76% |
| 2014 Q3 | -40.67 Million SEK | 14.9% |
| 2014 Q1 | -41.38 Million SEK | 16.05% |
| 2014 FY | -100.04 Million SEK | -102.92% |
| 2014 Q4 | -100.04 Million SEK | -145.96% |
| 2014 Q2 | -47.79 Million SEK | -15.49% |
| 2013 Q3 | -54.91 Million SEK | 7.11% |
| 2013 Q4 | -49.3 Million SEK | 10.21% |
| 2013 Q2 | -59.11 Million SEK | -22.48% |
| 2013 Q1 | -48.26 Million SEK | 17.93% |
| 2013 FY | -49.3 Million SEK | 16.16% |
| 2012 Q2 | -68.6 Million SEK | 15.97% |
| 2012 Q3 | -65.48 Million SEK | 4.55% |
| 2012 Q1 | -81.64 Million SEK | 9.83% |
| 2012 Q4 | -58.8 Million SEK | 10.2% |
| 2012 FY | -58.8 Million SEK | 35.05% |
| 2011 Q2 | -106.16 Million SEK | -4447.82% |
| 2011 FY | -90.54 Million SEK | -15833.93% |
| 2011 Q4 | -90.54 Million SEK | 7.28% |
| 2011 Q3 | -97.65 Million SEK | 8.01% |
| 2011 Q1 | -2.33 Million SEK | -310.79% |
| 2010 Q4 | -568.26 Thousand SEK | 0.0% |
| 2010 FY | -568.26 Thousand SEK | -49.37% |
| 2009 FY | -380.44 Thousand SEK | 46.96% |
| 2008 FY | -717.28 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -289.237% |
| Ziccum AB (publ) | -2.13 Million SEK | -9010.903% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -921.511% |
| BioArctic AB (publ) | -606.58 Million SEK | 67.902% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -289.915% |
| Mendus AB (publ) | -96.29 Million SEK | -102.193% |
| Genovis AB (publ.) | -43.94 Million SEK | -343.094% |
| Intervacc AB (publ) | -88.16 Million SEK | -120.848% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 1049.293% |
| Active Biotech AB (publ) | -33.2 Million SEK | -486.446% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 465.819% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -394.388% |
| Aptahem AB (publ) | 2.9 Million SEK | 6793.845% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 41.64% |
| Kancera AB (publ) | -45.69 Million SEK | -326.114% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 40.832% |
| Fluicell AB (publ) | -2.76 Million SEK | -6946.688% |
| Saniona AB (publ) | 40.44 Million SEK | 581.371% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -509.829% |
| Biovica International AB (publ) | -58.73 Million SEK | -231.478% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -330.59% |
| AcouSort AB (publ) | -23.98 Million SEK | -711.724% |
| Xintela AB (publ) | -7.8 Million SEK | -2393.277% |
| Abliva AB (publ) | -57.24 Million SEK | -240.147% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -136.856% |
| OncoZenge AB (publ) | -12.62 Million SEK | -1441.934% |
| Amniotics AB (publ) | -5.63 Million SEK | -3357.031% |
| 2cureX AB (publ) | -13.4 Million SEK | -1352.66% |
| CombiGene AB (publ) | -101.44 Million SEK | -91.936% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -8909.718% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 3705.556% |
| Camurus AB (publ) | -1.16 Billion SEK | 83.292% |
| Corline Biomedical AB | -17.01 Million SEK | -1044.486% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -132.497% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -40.936% |
| I-Tech AB | -83.26 Million SEK | -133.84% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 244.535% |
| Cyxone AB (publ) | -16.67 Million SEK | -1067.966% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -248.388% |
| Biosergen AB | -1.88 Million SEK | -10239.883% |
| Cantargia AB (publ) | -139.74 Million SEK | -39.323% |
| NextCell Pharma AB | -46.79 Million SEK | -316.109% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -50.353% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -562.629% |
| Nanologica AB (publ) | -9.38 Million SEK | -1973.924% |
| SynAct Pharma AB | -61.75 Million SEK | -215.263% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -809.176% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -1371.746% |
| LIDDS AB (publ) | -13.51 Million SEK | -1340.941% |
| Lipum AB (publ) | -8.46 Million SEK | -2200.059% |
| BioInvent International AB (publ) | -236.3 Million SEK | 17.606% |
| Alzinova AB (publ) | -21.22 Million SEK | -817.271% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -190.944% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -3658.02% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -132.503% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -20994.258% |
| Simris Alg AB (publ) | 85.07 Million SEK | 328.857% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -137.19% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 217.235% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -836.373% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -6451.144% |